>Revista de Hematología
>Year 2015, Issue 1
Baldovinos-Naranjo L, Rivera-Trujillo A, Hernández-Rodríguez S, Velázquez-Delgado G, Villaseñor-Aguirre Morelos Vil, Gómez-Guijosa MÁ
Multiple myeloma in a young patient
Rev Hematol Mex 2015; 16 (1)
PDF: 512.96 Kb.
Multiple myeloma is a haematological malignancy with the common
denominator in the production of M protein, and a variety of clinical
presentation that throughout history has required adjustments to the
definition of it, the vast majority of cases have been reported in the
seventh decade of life, and less than 1%, reported in patients under 30
years, without finding reports of patients younger than 20 years in our
country. This paper reports the case of an 18-year-old female patient
previously diagnosed with primary hyperthyroidism and chronic evolution
of anemic syndrome with IgG kappa monoclonal gammopathy,
without lytic lesions, hypercalcemia, or renal failure, with plasma cells
in bone marrow, without evidence of extramedullary plasmacytomas, in
who the diagnosis of symptomatic multiple myeloma was established
in conjunction with high beta 2 microglobulin, positive immunohistochemical
CD138, kappa chains in the bone biopsy. The presentation
differs from that reported for this age group.
||symptomatic multiple myeloma, M protein, beta 2 microglobulin, CD138, kappa chains, age.
Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2005;352:1163.
Marc SR, Klaus P, Iris B, Paul GR, Kenneth CA. Multiple myeloma. Lancet 2009;374:324-339.
Kapoor R, Bansal M, Sastri GJ, Sandhu MS, et al. Clinical spectrum and prognosis of multiple myeloma in patients younger than 30 years: Is it different from elderly? JK Science 2006;8:225-228.
Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975- 2007. Bethesda, MD: National Cancer Institute. (http://seer.cancer.gov/csr/1975_2007/ index.html.)
Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjrkholm M. Patterns of survival in multiple myeloma: a population- based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993- 1999.
Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med 1996;156:1463-1468.
Hewell GM, Alexanian R. Multiple myeloma in young persons. Ann Intern Med 1976;84:441-443.
De Queiroz E, et al. Multiple myeloma: A rare case in an 8-year-old child. Clin Lymphoma Myeloma Leuk. Article in press.
Kyle RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362- 1369.
Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013;122:4172.
Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345-351.
Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998;30:493-501.
Ludwig H, Durie BG, Bolejack V, Turesson I, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039-4047.
Geetha N, Jayaprakash M, Rekhanair A, Ramachandran K, Rajan B. Plasma cell neoplasm in the young. Br J Radiol 1999;72:1012-1015.
Ventura G, et al. Multiple myeloma associated with Epstein Barr virus in an AIDS patient. A case report. Eur J Hematol 1995;55:332-334.
Lenhoff S, Hjorth M, Westin J, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133: 389-396.
Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 2012;120:285-290.
Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
>Revista de Hematología
>Year 2015, Issue 1